New antibody combo aims to outsmart High-Risk myeloma
NCT ID NCT07029776
First seen Nov 06, 2025 · Last updated May 21, 2026 · Updated 28 times
Summary
This study tests whether two bispecific antibodies (teclistamab and talquetamab) given in sequence can improve survival in 50 people with high-risk multiple myeloma. Participants receive chemotherapy, stem cell collection, and antibody treatments. Those with remaining cancer cells get a stem cell transplant; others skip it. All continue with maintenance therapy. The goal is to see if this approach leads to complete remission and longer time without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72120, United States
Conditions
Explore the condition pages connected to this study.